Delving into the Latest Updates on Fentanyl Citrate with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Abstral Sublingual, E-Fen Buccal, Fentanyl citrate (JP17/USP)

+ [33]

Target

μ opioid receptor

Action

agonists

Mechanism

μ opioid receptor agonists(Mu opioid receptor agonists)

Therapeutic Areas

Nervous System DiseasesUrogenital DiseasesOther Diseases

Active Indication

Breakthrough PainCancer PainHyperemesis Gravidarum+ [1]

Inactive Indication

Anemia, Sickle CellBurnsChronic Pain+ [9]

Originator Organization

Rising Pharmaceuticals, Inc.

Active Organization

Istituto Gentili Srl

Grünenthal GmbH

Phoenix Labs

+ [5]

Inactive Organization

Cephalon, Inc.Teva Branded Pharmaceutical Products R&D LLCKyowa Kirin Services Ltd.

+ [6]

License Organization

Kunwha Pharmaceutical Co., Ltd.

Daiichi Sankyo Co., Ltd.

Collegium Pharmaceutical, Inc.

+ [7]

Drug Highest PhaseApproved

First Approval Date

United States (19 Feb 1968),

Anesthesia

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC28H36N2O8

InChIKeyIVLVTNPOHDFFCJ-UHFFFAOYSA-N

CAS Registry990-73-8

Fentanyl and its analog valerylfentanyl (CAS: 122882-90-0) represent a major toxicological threat amid the ongoing opioid crisis. Using an integrative in silico approach (STopTox, ProTox 3.0, TEST 5.1.2, VEGA QSAR, Percepta, ADMETlab, admetSAR), we evaluated key toxicity end points relevant to clinical and forensic toxicology. Valerylfentanyl exhibited high acute toxicity with predicted LD₅₀ values as low as 18.0 mg/kg (ProTox) and 150.13 mg/kg (TEST). Both compounds showed strong potential to inhibit the hERG potassium channel (95.7% for valerylfentanyl), indicating a substantial risk of cardiotoxicity. Predicted organ-specific effects were most prominent in the lungs (94%), cardiovascular (89%), and gastrointestinal systems (81%), with moderate impact on kidneys and blood. Skin irritation potential was high (up to 81.6%), while genotoxicity remained low, though valerylfentanyl showed non-negligible mutagenic probability in some models. The structural analysis identified piperidine-related toxicophores responsible for these effects. Our findings confirm that minor structural modifications can significantly alter toxicological profiles. These results underscore the application of integrated in silico approach for rapid, ethical hazard identification of emerging NPS, supporting their critical application in both clinical and forensic toxicology.

01 Jan 2026·AMERICAN JOURNAL OF EMERGENCY MEDICINE

Femoral nerve block vs IV fentanyl for hip fracture pain in the emergency department: A randomized double-blind clinical trial

Article

Author: Sanri, Erkman ; Kudu, Emre ; Gunduz, Osman Hakan ; Unal, Emir ; Altunbaş, Erhan ; Karacabey, Sinan

BACKGROUND:

Hip fractures frequently cause severe pain and functional decline in adults presenting to emergency departments (EDs). Although intravenous (IV) opioids are widely used for pain control, their use may be limited by adverse effects, especially in patients with comorbidities or cognitive impairment. Ultrasound-guided femoral nerve block (FNB) offers a regional analgesic technique that may provide effective pain relief while reducing opioid-related complications. However, comparative randomized trials in the ED setting remain limited.

METHODS:

In this single-center, randomized, double-blind clinical trial, adult patients with radiologically confirmed hip fractures were assigned to receive either ultrasound-guided FNB (20 mL 0.5 % bupivacaine) or IV fentanyl (1 μg/kg). To preserve blinding, patients in each group received a placebo injection mimicking the alternative treatment. Pain severity was measured at baseline and 20 min post-intervention using the Numeric Pain Rating Scale or the Pain Assessment in Advanced Dementia Scale (PAINAD), based on cognitive status. The primary outcome was change in pain score at 20 min. Secondary outcomes included rescue analgesia requirement within four hours and adverse events.

RESULTS:

A total of 104 patients were enrolled and randomized. The FNB group experienced greater median pain reduction compared to the fentanyl group (4 [IQR 3-5] vs. 2 [IQR 2-3]; median difference: 2, 95 % CI: 1-2). Rescue analgesia was required in 21.1 % of FNB patients versus 61.5 % in the fentanyl group. Adverse events were observed only in the fentanyl group, including nausea (23 %), dizziness (15 %), headache (9.6 %), and hypotension (5.7 %). No FNB-related complications were reported. Subgroup analysis showed consistent efficacy among cognitively impaired patients.

CONCLUSION:

FNB resulted in superior analgesia, fewer side effects, and lower need for rescue opioids compared to IV fentanyl. Additionally, FNB has shown an effective and safe pain control in patients with cognitive impairment compared to patients without cognitive impairment.

TRIAL REGISTRATION:

ClinicalTrials.gov Identifier: NCT06862154.

01 Dec 2025·LANCET

Comparison of inhalational methoxyflurane, intranasal fentanyl, and intravenous morphine for treatment of prehospital acute pain in Norway (PreMeFen): a randomised, non-inferiority, three-arm, phase 3 trial

Article

Author: Heyerdahl, Fridtjof ; Smalberget, Live ; Simensen, Randi ; Rehn, Marius ; Hagemo, Jostein ; Thorsen, Kjetil ; Fjose, Lars Olav ; Olsen, Inge Christoffer

BACKGROUND:

Adequate pain control is essential; however, acute pain is often undertreated in prehospital care. This study aimed to evaluate three analgesic regimens for treating acute pain in an ambulance setting.

METHODS:

PreMeFen is a randomised, open-label, non-inferiority, three-arm, phase 3 trial conducted in the working areas of the ground ambulance service of the Innlandet Hospital Trust, Norway. Patients aged 18-69 years and 70 years and older with traumatic or medical acute pain scoring 4 or higher on the Numeric Rating Scale (NRS) were randomly assigned (1:1:1) to receive in titration doses 3 mL inhalational methoxyflurane, 50 μg or 100 μg intranasal fentanyl, or 0·05 mg/kg or 0·1 mg/kg intravenous morphine, respectively, depending on the age group. The primary endpoint was change in pain NRS score from baseline to 10 min after treatment start and was analysed per protocol. The non-inferiority margin was 1·3. This trial is registered with ClinicalTrials.gov (NCT05137184) and is completed.

FINDINGS:

Between Nov 12, 2021, and April 22, 2023, 632 patients were assessed for eligibility, and 338 were randomly assigned to methoxyflurane (n=112), fentanyl (n=115), or morphine (n=111). 281 patients were included in the per-protocol population. 145 (52%) of 281 patients were female and 136 (48%) were male. Median age was 61 years (IQR 47-75). The baseline NRS score was 7·6 (SD 1·8). Mean NRS score changes after 10 min were -3·31 (SD 2·67) for methoxyflurane, -1·98 (2·28) for fentanyl, and -2·74 (2·12) for morphine. Comparing changes in mean NRS score while adjusting for baseline showed that methoxyflurane was non-inferior to fentanyl (-1·33 [95% CI -2·01 to -0·64]) and morphine (-0·36 [-1·03 to 0·31]). Intranasal fentanyl was not non-inferior to morphine at 10 min (0·91 [0·27 to 1·55]). Adverse events occurred in 26 (24%) of 109 patients in the morphine group, 27 (24%) of 112 in the fentanyl group, and 24 (22%) of 111 in the methoxyflurane group. Two serious adverse events, respiratory depression (grade 2) and loss of consciousness (grade 3), occurred in the same patient in the methoxyflurane group. There were no treatment-related deaths.

INTERPRETATION:

Inhalational methoxyflurane is non-inferior to intranasal fentanyl and intravenous morphine for acute pain management in the prehospital environment, assessed 10 min after administration. Inhalational methoxyflurane serves as a valuable non-intravenous alternative in the early phase of treatment and might bridge the gap to longer-acting analgesics.

FUNDING:

Norwegian Air Ambulance Foundation and Innlandet Hospital Trust.

79

News (Medical) associated with Fentanyl Citrate

01 May 2026

·www.einpresswire.com

Renewal Springs Detox Opens in Oklahoma City to Address Fourth Wave of Opioid Crisis

New medical detox program expands access to safe withdrawal care as fentanyl and meth drive overdose rates across Oklahoma. Detox is no longer a step that can be delayed or done without medical oversight. Renewal Springs exists to provide that level of care when it matters most.” — Tara McDonald OKLAHOMA CITY, OK, UNITED STATES, May 1, 2026 / EINPresswire.com / -- Renewal Springs Detox, a new medical detox center in Oklahoma City, has officially opened its doors with a clear and urgent mission: to help combat Oklahoma’s role in the “fourth wave” of the opioid epidemic, defined by the dangerous co-use of fentanyl and methamphetamine. Across Oklahoma, overdose deaths have surged in recent years, with state data showing that methamphetamine is now involved in a majority of overdose cases, often in combination with synthetic opioids like fentanyl. This shift has created a more complex and volatile addiction landscape, one that requires a higher level of clinical care during the earliest stages of recovery. Renewal Springs Detox was designed to meet that need. The program provides 24/7 medically supervised detox, offering individuals a safe and structured environment to withdraw from alcohol, opioids, benzodiazepines, stimulants, and polysubstance use. With continuous medical monitoring, individualized withdrawal management, and a focus on patient dignity, the facility aims to stabilize clients physically while preparing them for ongoing treatment. “Oklahoma is facing a different kind of addiction crisis than it did even five years ago,” said Executive Director Tara McDonald. “The overlap between meth and fentanyl has raised the stakes. Detox is no longer a step that can be delayed or done without medical oversight. Renewal Springs exists to provide that level of care when it matters most.” The fourth wave of the opioid epidemic has been marked not only by increased overdose risk, but also by more severe withdrawal presentations and higher rates of relapse when individuals do not receive proper stabilization. Many people entering treatment today are managing multiple substances at once, often alongside underlying mental health conditions. Renewal Springs addresses this reality through a clinically grounded approach to drug and alcohol detox in Oklahoma City . Each client receives an individualized detox plan tailored to their substance use history, physical health, and psychological needs. The goal is not to just manage symptoms, but to create a safe entry point into long-term recovery. The program is part of the Pathways Recovery Centers network and operates as a sister program to Country Road Recovery Center, which has provided high-quality addiction treatment services in Oklahoma for the past five years. Together, the programs offer a connected continuum of care, allowing clients to move seamlessly from medical detox in OKC into residential treatment and ongoing recovery support. This continuity is especially critical in the current landscape. Gaps between detox and the next level of care are one of the most common points of relapse. By integrating detox into a broader treatment network, Renewal Springs helps reduce those gaps and improve long-term outcomes. The opening of Renewal Springs represents more than the addition of a new facility. It reflects a broader effort to strengthen addiction treatment in Oklahoma, particularly at a time when the risks associated with substance use have never been higher. “Every person who walks through our doors is taking a significant step,” McDonald added. “Our responsibility is to meet that step with the highest standard of care and to help them move forward into recovery with stability and support.” To learn more about detox services in Oklahoma City at Renewal Springs or to inquire about admission, visit https://www.renewalspringsokc.com . Tara McDonald Renewal Springs +1 405 766-3500 email us here Visit us on social media: LinkedIn Instagram Facebook Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

22 Apr 2026

·www.einpresswire.com

Intensive Treatment Systems Expands Addiction Care Access with 24/7 Intake Hub in West Phoenix

PHEONIX, AZ, UNITED STATES, April 22, 2026 / EINPresswire.com / -- Intensive Treatment Systems (ITS), a leading Arizona-based provider of substance use disorder treatment, is expanding awareness of its 24/7 access model as more individuals seek immediate, accessible care for addiction across the state. With rising demand for opioid, fentanyl, alcohol, and polysubstance treatment, many individuals and families continue to face delays in accessing care. Intensive Treatment Systems is addressing this gap through walk-in availability, same-day intake, and a statewide network of clinics designed to reduce barriers and provide support when it is needed most. Medication Assisted Treatment (MAT), one of the clinic’s core services, combines FDA-approved medications with counseling and behavioral therapies to treat substance use disorders . This evidence-based approach helps reduce cravings, manage withdrawal symptoms, and support long-term recovery outcomes. “Access to care is one of the biggest challenges in addiction treatment,” said a spokesperson for Intensive Treatment Systems. “By offering 24/7 support, walk-in services , and same-day intake, we are removing obstacles so individuals can begin treatment the moment they are ready.” Intensive Treatment Systems provides comprehensive outpatient addiction treatment across multiple Arizona locations, including Phoenix, Glendale, Mesa, Scottsdale, and San Tan Valley. Services include individual counseling, group therapy, family support, psychiatric care, and intensive outpatient programs (IOP), alongside peer support from individuals with lived recovery experience. The organization also offers specialized programs for vulnerable populations, including pregnant women, veterans, and individuals with co-occurring mental health conditions. Integrated care ensures that both physical and behavioral health needs are addressed as part of the recovery process. In addition to clinic-based care, Intensive Treatment Systems operates a mobile treatment unit to extend services into the community, improving access for individuals who may face transportation or logistical challenges. Transportation to and from clinics is also available, further reducing barriers to entry. The organization’s nearly 30 years of experience, combined with partnerships with hospitals, justice systems, and AHCCCS, positions it as a trusted provider of addiction treatment in Arizona. Its approach emphasizes dignity, community support, and long-term recovery rather than short-term solutions. For individuals unsure where to begin, the clinic encourages simple first steps such as walking into a location, calling a care advocate, or requesting a same-day appointment. The focus remains on meeting individuals where they are and guiding them toward recovery without judgment. As conversations around addiction continue to evolve, Intensive Treatment Systems remains committed to providing accessible, evidence-based care that helps individuals rebuild their lives and reconnect with their communities. About Intensive Treatment Systems Intensive Treatment Systems is an Arizona-based addiction treatment provider offering Medication Assisted Treatment, counseling, and integrated outpatient care. With multiple locations across Phoenix, Glendale, Mesa, and surrounding areas, the organization provides 24/7 access, same-day intake, and community-focused services designed to support long-term recovery from substance use disorders. Emma Sivess Unlimited Content +44 7799 180194 email us here Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

22 Apr 2026

·www.nutriband.com

About AVERSA™ Abuse-Deterrent Transdermal Technology

ORLANDO, Fla., April 22, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), today announced that its CEO and Co-Founder, Gareth Sheridan has featured on the latest episode of the Jack Neel Podcast to discuss the opioid crisis, the Company’s AVERSA technology and the opportunity for Nutriband to improve the safety profile of easily abused medications. Interested shareholders may find the link to the latest youtube episode here https://youtu.be/HB6E7TxGXqg?si=VU6c57saNbdzxraH. The Episode can also be found on Spotify, iTunes, Amazon music and www.jackneel.com Nutriband's AVERSA™ abuse-deterrent transdermal technology incorporates aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. The AVERSA™ abuse-deterrent technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while making sure that these drugs remain accessible to those patients who really need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia. We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. The Company's website is www.nutriband.com. Any material contained in or derived from the Company's websites or any other website is not part of this press release. Certain statements contained in this press release, including, without limitation, statements containing the words ‘'believes," "anticipates," "expects" and words of similar import, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company's ability to develop its proposed abuse-deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company's business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's Form S-1, Forms 10-K’s and Forms 10-Q’s, and the Company's other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.

100 Deals associated with Fentanyl Citrate

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D01399	Fentanyl Citrate	N02AB03 N01AH01	DB00813

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Pain	United States	Adalvo Ltd.	16 Jul 2009
Breakthrough Pain	European Union	Phoenix Labs	04 Apr 2008
Breakthrough Pain	Iceland	Phoenix Labs	04 Apr 2008
Breakthrough Pain	Liechtenstein	Phoenix Labs	04 Apr 2008
Breakthrough Pain	Norway	Phoenix Labs	04 Apr 2008
Cancer Pain	United States	Cephalon, Inc.	04 Nov 1998
Hyperemesis Gravidarum	China	Yichang Humanwell Pharmaceuticals Co., Ltd.	01 Jan 1981
Anesthesia	United States	Rising Pharmaceuticals, Inc.	19 Feb 1968

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Head and Neck Neoplasms	Phase 3	Italy	L. Molteni & C. dei F.lli Alitti Società di Esercizio SpA	01 Sep 2014
Respiratory Insufficiency	Phase 3	-	BioDelivery Sciences International, Inc.	01 Jun 2008
Chronic Pain	Phase 3	United States	Cephalon, Inc.	01 Dec 2006
Complex Regional Pain Syndromes	Phase 3	United States	Cephalon, Inc.	01 Sep 2005
Low Back Pain	Phase 3	United States	Cephalon, Inc.	01 Sep 2005
Neuralgia	Phase 3	United States	Cephalon, Inc.	01 Sep 2005
Neuralgia, Postherpetic	Phase 3	United States	Cephalon, Inc.	01 Sep 2005
Neoplasms	Phase 3	-	Cephalon, Inc.	01 Jun 2004
Dyspnea, Paroxysmal	Phase 2	Germany	Teva Branded Pharmaceutical Products R&D LLC	01 Mar 2013
Lung Cancer	Phase 2	Germany	Teva Branded Pharmaceutical Products R&D LLC	01 Mar 2013

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03476369 (FACTPCI, CTgov)	Phase 4	-	45	Fentanyl+Ticagrelor 90Mg Tablet (Fentanyl and Crushed Ticagrelor)	yccimtvwat(qoguabyioy) = pixhblrmwa ckaujkrmho (earmjzwmlr, aqhudmirdu - gafnoyaryd) View more	-	04 Feb 2026
				Fentanyl+Ticagrelor 90Mg Tablet (Fentanyl and Non-crushed Ticagrelor)	yccimtvwat(qoguabyioy) = ieoxuitwat ckaujkrmho (earmjzwmlr, rqzdlwlyad - mhpiuecvvm) View more
NCT06862154 (Pubmed \| Am J Emerg Med)	Phase 4	Fracture pain	104	Ultrasound-guided Femoral Nerve Block (FNB) 0.5% bupivacaine	wjxbxlvdqs(ppgsekqqtz) = oclwbozggc fnllfhaaot (jfdylvvzyg, 3 - 5) View more	Positive	01 Jan 2026
				IV Fentanyl	wjxbxlvdqs(ppgsekqqtz) = cosssjpdmj fnllfhaaot (jfdylvvzyg, 2 - 3) View more
NCT06862154 (CTgov)	Phase 4	Analgesia \| Femoral Neuropathy \| Femoral Neck Fractures ... View more	104	Femoral Nerve Block (Femoral Nerve Block)	fvlumgdakq(oyoweqjajf) = stjatusbvq ckhxldpprf (okreyotqio, ujsxluveuu - ywqnegvxkd) View more	-	05 Dec 2025
				Fentanyl (IV Analgesia-Fentanyl)	fvlumgdakq(oyoweqjajf) = epviplgluz ckhxldpprf (okreyotqio, owgbevkosp - caazketnej) View more
NCT05137184 (PreMeFen, Pubmed \| Lancet)	Phase 3	Acute Pain	281	Inhalational methoxyflurane	rqsitgfdrf(ntkugragwk) = wkginueyfa krgzwtpxga (ztcdltwhkl ) View more	Positive	01 Dec 2025
				Intranasal fentanyl	rqsitgfdrf(ntkugragwk) = iwddnrqvlh krgzwtpxga (ztcdltwhkl )
NCT03726268 (OSPREy, CTgov)	Phase 4	Pain, Postoperative	907	Methadone (Short-stay, IV Methadone)	ekteqxosgr(tpqboedodd) = aesleekzxy slncnjgwua (vxyzffnete, 15.50) View more	-	19 Nov 2025
				Fentanyl+Hydromorphone+Sufentanil+Morphine (Short-stay, IV Short-acting Opioids)	ekteqxosgr(tpqboedodd) = dipfyqmnwn slncnjgwua (vxyzffnete, 11.60) View more
ARVO2025	Not Applicable	-	65	Ketamine (0.5 mg/kg) + Midazolam (0.05 mg/kg)	szdqjtyewi(klcrisoegb) = hbzpfyqwtf petjbepcky (laderzfiyr ) View more	Positive	04 May 2025
				Fentanyl (1 μg/kg) + Midazolam (0.05 mg/kg)	szdqjtyewi(klcrisoegb) = hqeszehpqx petjbepcky (laderzfiyr ) View more
NCT04230681 (CTgov)	Early Phase 1	Sleep Apnea, Obstructive \| Tonsillitis	189	Hydromorphone (Hydromorphone)	fiovpjgbyz = biizxfqdph jkieftytyj (lrsodwlvxk, rqiduxbvyw - eqryyaliie) View more	-	18 Dec 2024
				Fentanyl (Fentanyl)	fiovpjgbyz = hyrbsxxlep jkieftytyj (lrsodwlvxk, dlcegootjw - ygxxgtowtw) View more
WCLC2024 Manual	Phase 3	Sedation	84	Midazolam with Fentanyl	tlqvfjkvby(dnhhzyryrq) = syrxihfvzg okrnubiwbd (judnnyxlpa ) View more	Positive	07 Sep 2024
				Midazolam with Placebo	tlqvfjkvby(dnhhzyryrq) = cxubjyquhd okrnubiwbd (judnnyxlpa ) View more
NCT03435003 (CTgov)	Phase 4	Postoperative Nausea and Vomiting \| Vomiting	83	dexmedetomidine+Total intravenous anesthesia+Fentanyl+scopolamine transdermal+Compazine+sugammadex+Reglan+Propofol+Dexamethasone+Ondansetron+Aprepitant 80 mg Oral Capsule (Intervention Arm)	wyfmuujtup = sfxiydmtms hcwaredxwg (pvmxhhifge, dmswfygeys - pqwvpibguf) View more	-	14 Feb 2024
				Compazine+sugammadex+Reglan+Sevoflurane+Dexamethasone+desflurane+Ondansetron (Control Arm)	wyfmuujtup = dqfpqioyti hcwaredxwg (pvmxhhifge, tomqiduuwy - hrjfccekqh) View more
NCT03115151 (CTgov)	Phase 4	Pain	46	Fentanyl+Bupivacaine (Patient-Controlled Epidural Analgesia)	kijstrfiad(vnqtfwddsi) = sjwmqeogil ntubdtiizh (hgbslwfbji, 24.69) View more	-	26 Oct 2023
				Hydromorphone (Intravenous Patient-controlled Analgesia)	kijstrfiad(vnqtfwddsi) = kemruvhjng ntubdtiizh (hgbslwfbji, 25.41) View more